The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC).
 
Daneng Li
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Merck; Sumitomo Pharma Oncology; Tersera; TransThera Biosciences
Speakers' Bureau - Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst); Brooklyn ImmunoTherapeutics (Inst)
 
Kun-Ming Rau
No Relationships to Disclose
 
Ming-Lung Yu
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Gilead Sciences
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; Gilead Sciences
Research Funding - Abbvie; Bristol-Myers Squibb; Gilead Sciences
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Gilead Sciences
 
Hong Jae Chon
Consulting or Advisory Role - AstraZeneca; Bayer; BMS; Celgene Cancer Care Links/BMS; Eisai; Green Cross; Menarini; MSD Oncology; Ono Pharmaceutical; Roche; Sanofi; SERVIER; Sillajen
Speakers' Bureau - Bayer; BMS; Celgene/Bristol-Myers Squibb; Dong-A ST; Eisai; Menarini; Roche; Sanofi; SERVIER
Research Funding - Boryung (Inst); Dong-A ST (Inst); Roche (Inst)
 
Hsueh-Chou Lai
No Relationships to Disclose
 
Meredith Pelster
Honoraria - Castle Biosciences (I)
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 1200 Pharma (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Codiak Biosciences (Inst); Compass Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Elevation Oncology (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Immune-Onc Therapeutics (Inst); Leap Therapeutics (Inst); Novartis (Inst); OncXerna Therapeutics (Inst); Panbela Therapeutics (Inst); Revolution Medicines (Inst); SQZ Biotechnology (Inst); Surface Oncology (Inst); Tachyon Therapeutics (Inst); Translational Genomics Research Institute (Inst); TransThera Sciences (Nanjing), Inc. (Inst); ZielBio (Inst)
 
Stuart K. Roberts
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
 
Oxana V. Crysler
Research Funding - ACCRU (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
Gina M. Vaccaro
Consulting or Advisory Role - Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Exelixis; GlaxoSmithKline; Helsinn Therapeutics; Incyte; MSD; Pfizer; QED Therapeutics; SERVIER; Taiho Pharmaceutical
Speakers' Bureau - Incyte
Research Funding - Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; E.R. Squibb Sons, LLC; Eisai; Foundation Medicine
 
Mark Sanders Womack
No Relationships to Disclose
 
Ju Won Kim
No Relationships to Disclose
 
Jin-Mo Yang
No Relationships to Disclose
 
Hyung-Don Kim
No Relationships to Disclose
 
Jonathan Hill
Employment - Surface Oncology
Stock and Other Ownership Interests - Surface Oncology
Research Funding - Surface Oncology
Patents, Royalties, Other Intellectual Property - Surface Oncology
Travel, Accommodations, Expenses - Surface Oncology
 
VIENNA Lynn REICHERT
Employment - Coherus BioSciences; Deciphera; Surface Oncology
Stock and Other Ownership Interests - Coherus BioSciences; Deciphera; Surface Oncology
Consulting or Advisory Role - Kineta (I)
 
Ricard Masia
Employment - Surface Oncology
Stock and Other Ownership Interests - Surface Oncology
Consulting or Advisory Role - Coherus BioSciences
Patents, Royalties, Other Intellectual Property - Surface Oncology
 
Lauren C Harshman
Employment - Surface Oncology
Stock and Other Ownership Interests - Surface Oncology
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Blueprint Medicines; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks